Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic macular edema (DME) who have previously responded to at least 2 ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb. 3 in the Journal of the American Medical ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3 ...

Most Americans would prefer brand-name drugs—but end up buying generic versions because of the cost, new consumer research ...

If you live with type 2 diabetes, it’s important to make diet choices that help you stabilize your blood sugar, manage your symptoms, and reduce your risk of severe symptoms. According to ...

This is what you need to keep in the back of your mind as you compare Kraft Heinz (NASDAQ: KHC) to Coca-Cola (NYSE: KO). Both ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.